PRESS RELEASES

Archives

  

December 18, 2014 - OptiNose to Present at the 33rd Annual J.P. Morgan Healthcare Conference
November 26, 2014 - FDA Issues Complete Response Letter for AVP-825 New Drug Application
October 31, 2014 - OptiNose Announces Publication of Pivotal Phase III Results for Investigational Migraine Treatment Developed by OptiNose Using Bi-Directional™ Breath Powered™ Technology
August 4, 2014 - OptiNose Completes Series C-1 Financing
June 12, 2014 - OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs and Commercialization
June 10, 2014 - OptiNose Announces Positive Results of COMPASS: A Head-to-Head Comparison of a New Migraine Treatment Using Bi-Directional™ Breath Powered™ Technology (AVP-825) versus Oral Sumatriptan
March 26, 2014 - OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
January 30, 2014 - New Drug Application Submitted for Migraine Treatment Using OptiNose Technology